Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 104(2): 361-8, 2011 Jan 18.
Article in English | MEDLINE | ID: mdl-21063398

ABSTRACT

BACKGROUND: Intra-tumour genetic heterogeneity has been reported in both leukaemias and solid tumours and is implicated in the development of drug resistance in CML and AML. The role of genetic heterogeneity in drug response in solid tumours is unknown. METHODS: To investigate intra-tumour genetic heterogeneity and chemoradiation response in advanced cervical cancer, we analysed 10 cases treated on the CTCR-CE01 clinical study. Core biopsies for molecular profiling were taken from four quadrants of the cervix pre-treatment, and weeks 2 and 5 of treatment. Biopsies were scored for cellularity and profiled using Agilent 180k human whole genome CGH arrays. We compared genomic profiles from 69 cores from 10 patients to test for genetic heterogeneity and treatment effects at weeks 0, 2 and 5 of treatment. RESULTS: Three patients had two or more distinct genetic subpopulations pre-treatment. Subpopulations within each tumour showed differential responses to chemoradiotherapy. In two cases, there was selection for a single intrinsically resistant subpopulation that persisted at detectable levels after 5 weeks of chemoradiotherapy. Phylogenetic analysis reconstructed the order in which genomic rearrangements occurred in the carcinogenesis of these tumours and confirmed gain of 3q and loss of 11q as early events in cervical cancer progression. CONCLUSION: Selection effects from chemoradiotherapy cause dynamic changes in genetic subpopulations in advanced cervical cancers, which may explain disease persistence and subsequent relapse. Significant genetic heterogeneity in advanced cervical cancers may therefore be predictive of poor outcome.


Subject(s)
Antineoplastic Agents/therapeutic use , Genetic Heterogeneity , Uterine Cervical Neoplasms/genetics , Adult , Aged , Combined Modality Therapy , Female , Humans , Middle Aged , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/radiotherapy
3.
Aviat Space Environ Med ; 61(12): 1116-20, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2285401

ABSTRACT

When rats are returned to a normoxic environment after chronic exposure to hypoxia, they manifest a striking drinking response. Earlier studies had shown that the drinking response was an inverse linear function of the percentage of oxygen in the air to which the rats had been exposed. An objective of the present experiment was to measure the post-hypoxic drinking response at intervals during a 71-d exposure to an atmosphere containing 12% oxygen in nitrogen to assess whether the response could be observed throughout this entire period. The results suggest that the response continued unabated throughout the duration of exposure to hypoxia. The mechanism(s) accounting for the posthypoxic drinking response cannot be stated with certainty. However, the results of these studies indicate that administration of the betra-adrenoceptor antagonist, propranolol (6 mg/kg, i.p.), failed to affect the magnitude of the drink following return from hypoxia to normoxia. Hence, it is unlikely that the posthypoxic drinking response is mediated by an increase in beta-adrenergic activity.


Subject(s)
Body Water/physiology , Drinking/physiology , Hypoxia/physiopathology , Adaptation, Physiological , Animals , Atmosphere Exposure Chambers , Hematocrit , Hemoglobins/metabolism , Male , Rats , Rats, Inbred Strains , Time Factors
4.
Clin Sci (Lond) ; 75(2): 143-6, 1988 Aug.
Article in English | MEDLINE | ID: mdl-3409631

ABSTRACT

1. Acute metabolic effects of sodium fluoride therapy were analysed among 41 osteoporotic patients already receiving large calcium supplements, 33 of whom underwent simultaneous metabolic balance studies. 2. Mean serum calcium fell transiently within 24-48 h by 0.03 +/- 0.07 (SD) mmol/l (P less than 0.01) and phosphorus by 0.06 +/- 0.08 (SD) mmol/l (P less than 0.001). In a subgroup, ionized calcium fell and biologically active parathyroid hormone (bio-PTH) rose more than fivefold (P less than 0.01). Urine calcium rose after an insignificant fall. 3. Pretreatment calcium and phosphorus balances were significantly positive and did not change overall during the first 8 days of treatment. However, on analysing balances in two groups relative to serum changes, in patients whose serum levels changed least sodium fluoride increased faecal calcium (P less than 0.025) and phosphorus (P less than 0.01) and reduced calcium balance (P less than 0.01), giving a mean balance difference between the two groups of 2.1 mmol daily (P less than 0.001). 4. Very small changes in serum levels therefore indicate well-marked metabolic responses: sodium fluoride acutely stimulates bio-PTH activity and must also enhance mineral uptake from circulation into tissue(s). By separate and opposing action(s) it inhibits intestinal calcium and phosphorus absorption, predominantly in those whose serum levels remain stable. All these effects may be relevant to long-term therapeutic results.


Subject(s)
Calcium/blood , Homeostasis/drug effects , Osteoporosis/drug therapy , Parathyroid Hormone/blood , Phosphorus/blood , Sodium Fluoride/therapeutic use , Aged , Dihydroxycholecalciferols/blood , Female , Humans , Hydroxyapatites/therapeutic use , Male , Middle Aged , Osteoporosis/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...